Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05799131
Other study ID # QBX-RADAR
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 1, 2023
Est. completion date July 31, 2025

Study information

Verified date March 2023
Source QualiMed Innovative Medizinprodukte GmbH
Contact Dorien Haesen, PhD
Phone +32 11 28 69 48
Email dorien.haesen@archerresearch.eu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to evaluate the safety and performance of the QBX stent system in the treatment of PAD by reporting of peri- and postoperative complications, including major adverse vascular events (MAVE), Vascular Access Site Complications (VASCs) and bleeding at puncture site, and by evaluating the prevalence of Target Vessel Revascularization (TVR), amputations, procedural success, device performance, reduction in percentage diameter stenosis post-procedure compared to pre-procedure, artery patency, return to normal activity, Rutherford and Fontaine classification, quality of life (QoL), Ankle Brachial Index (ABI), and hospital- and patient-related costs in a prospectively maintained database.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date July 31, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient eligible for implantation of a peripheral balloon-expandable stent. - Target lesion is an occlusion or diameter stenosis is =50% by visual estimate. - Target lesion is a de novo or restenotic lesion. - Target lesion is located in the external iliac artery (EIA), internal iliac artery (IIA), common iliac artery (CIA), superficial femoral artery (SFA) and/or deep femoral artery (DFA). Bilateral treatment of the target lesions is allowed. There are no restrictions on the number of target lesions treated with QBX or the number of stents used. Kissing stents and overlapping stents are allowed to treat the target lesions. - Patient suffers from mild to intermittent claudication (Rutherford 1-3) or critical limb ischemia (Rutherford 4-5). - Patients with TASC A, B, C and D lesions. - Patient = 18 years of age at study entry. - Patient and investigator signed and dated the informed consent form prior to the index-procedure. Exclusion Criteria: - Age < 18 y. - Pregnant women, women who are currently breastfeeding, women of childbearing potential who are not using an effective method of contraception, or women planning to become pregnant during the course of the study. - Patients with Rutherford 0 and 6. - Patient received a different stent device than the study device for the target lesion. - Target lesion cannot be crossed with a guidewire (e.g. heavily calcified or excessively tortuous target lesion). - Reference vessel diameter is not suitable for the available stent design. - Target lesion was previously treated with a stent. - Target lesion is in a prosthetic vascular bypass graft or within 1 cm of a graft anastomosis. - Presence of significant stenosis (=50%) or occlusion of inflow tract not successfully treated before or during the index-procedure (success is measured as < 30% residual stenosis and absence of distal embolization). - Outflow: In case of treatment of iliac arteries: Inadequate distal runoff with > 50% stenosis of either the common femoral artery or both the superficial and deep femoral arteries. In case of treatment of the SFA: Absence of at least one patent runoff vessel with = 50% stenosis throughout its course (i.e., confirmed in-line patency to the level of the foot). Outflow can be treated before or during the index-procedure (success is measured as < 30% residual stenosis and absence of distal embolization). - Presence of active inflammation at the planned access site. - Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index-procedure. - Patients in severe renal failure (estimated Glomerular filtration rate (eGFR) < 25 mL/min/1.73m). Lab results are maximum 30 days old. - Patient has a persistent acute intraluminal thrombus of the target lesion. - Target lesion is in an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion. - Patient has an abdominal aortic aneurysm contiguous with an iliac artery target lesion. - Patient suffers from acute limb ischemia defined as any sudden decrease in limb perfusion causing a potential threat to limb viability. - Contraindication for anti-coagulation therapy (coagulopathy, etc.). - Patient has a known intolerance to contrast agents. If hypersensitivity to contrast agents in patients with prior reactions could be improved by premedication and changing the contrast agent, the patient can be included in the study. - Patients has a known hypersensitivity to the stent material (L605). - Patient has a life expectancy of <12 months. - Patient has a planned surgical intervention/procedure, interfering with the study (results), within 30 days of the study procedure. - Patient is considered to be hemodynamically unstable at onset of index-procedure. - Patient is currently participating in a confounding study. - Patient is unable to comply with the protocol or proposed follow-up visits. - Patient is unable / unwilling to provide informed consent.

Study Design


Intervention

Device:
QBX (5F/6F) Peripheral Balloon Expandable Stent System
The QBX Stent System is a flexible, balloon expandable stent, made of a cobalt chromium alloy manufactured by QualiMed Innovative Medizinprodukte GmbH. The design is suitable for peripheral vessel diameters from 5 to 10 mm. The QBX Stent System is available as 6F and 5F variations where the 6F system is mounted on an 0.035" over-the-wire delivery system, and the 5F is mounted on an 0.018" over-the-wire delivery system. Both are available in a full range of diameters and lengths.

Locations

Country Name City State
Belgium HIS IZZ Brussels
Belgium Ziekenhuis Oost-Limburg Genk Genk Limburg
Belgium Jessa Ziekenhuis Hasselt Limburg
Belgium AZ Groeninge Kortrijk West-Vlaanderen

Sponsors (1)

Lead Sponsor Collaborator
QualiMed Innovative Medizinprodukte GmbH

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the cumulative rate of MAVE. MAVE is defined as:
Device- or procedure-related death;
Target Lesion Revascularization (TLR) at 12 months, defined as a repeated procedure (endovascular or open surgery) due to a problem arising from the lesion (+1 cm proximally and distally to include edge phenomena) initially treated;
Device-related distal embolization that required hospitalization and/or subsequent intervention.
12-months follow-up
Secondary Rate of subjects with Vascular Access Site Complications (VASCs) within the first 24h after the index-procedure VASCs are defined as:
Hematoma/bleeding requiring transfusion
Arterial/venous occlusion/thrombosis
Severe vasospasm
Intimal injury/dissection
Pseudoaneurysm
Arteriovenous fistula
Vascular perforation or rupture
Arterial embolization distal to treatment site
Neuropathy
Retroperitoneal hematoma
24 hours
Secondary Intra-operative complication rate. Index-procedure
Secondary Post-operative complication rate. 12-months follow-up
Secondary Intra-operative absence of bleeding at puncture site. Index-procedure
Secondary Re-occlusion rate. Re-occlusion is defined as complete occlusion of the target lesion initially treated. 12-months follow-up
Secondary Target Vessel Revascularization (TVR) rate. TVR is defined as a procedure (endovascular or open surgical) due to a problem arising in the target vessel remote from the target lesion(s) initially treated. 12-months follow-up
Secondary Amputation rate Minor (below the ankle) and major (above the ankle) amputation rate at 12 months will be assessed. Major amputation rates must be reported as below-the-knee and above-the-knee amputations. 12-months follow-up
Secondary Procedural success. Procedural success is defined as a combination of technical success, device success and absence of procedural complications. Index-procedure
Secondary Technical success Technical success is defined as successful vascular access and completion of the endovascular procedure and immediate morphological success with less than 30% residual diameter reduction of the treated lesion on completion angiography. Index-procedure
Secondary Device success. Device success is defined as exact deployment of the device according to the instructions for use. Index-procedure
Secondary Device performance. Scored using the following components and a dedicated Scoring System (1: Very good, 2: Good, 3: Sufficient, Poor: 4):
Insertion through introducer sheath
Tracking to target site over guidewire
Crossability through of the lesion
Catheter pushability
Catheter shaft kink resistance
Stent radiopacity
Inflation time to Nominal diameter
Deflation time
Stent apposition
General usability of the QBX device
Index-procedure
Secondary Reduction in percentage diameter stenosis post-procedure compared to pre-procedure. Assessed via CT angio. Index-procedure
Secondary Artery patency. A duplex ultrasound will be performed to evaluate artery patency. If reliable duplex ultrasound assessment of artery patency is not possible, ABI is a good indication of patency. If ABI is abnormal and the patient is experiencing symptoms, a CT angio or other imaging module might be performed according to standard of care. 1-month follow-up
Secondary Artery patency. A duplex ultrasound will be performed to evaluate artery patency. If reliable duplex ultrasound assessment of artery patency is not possible, ABI is a good indication of patency. If ABI is abnormal and the patient is experiencing symptoms, a CT angio or other imaging module might be performed according to standard of care. 6-months follow-up
Secondary Artery patency. A duplex ultrasound will be performed to evaluate artery patency. If reliable duplex ultrasound assessment of artery patency is not possible, ABI is a good indication of patency. If ABI is abnormal and the patient is experiencing symptoms, a CT angio or other imaging module might be performed according to standard of care. 12-months follow-up
Secondary Return to normal activity. The number of days until return to normal activities will be assessed. 1-month follow-up
Secondary Distribution of Rutherford classes during follow-up as compared to baseline. The percentage of patients with Rutherford classes 0 to 6 will be determined. 1-month follow-up
Secondary Distribution of Rutherford classes during follow-up as compared to baseline. The percentage of patients with Rutherford classes 0 to 6 will be determined. 6-months follow-up
Secondary Distribution of Rutherford classes during follow-up as compared to baseline. The percentage of patients with Rutherford classes 0 to 6 will be determined. 12-months follow-up
Secondary Distribution of Fontaine stages during follow-up as compared to baseline. The percentage of patients with Fontaine stages I to IV will be determined. 1-month follow-up
Secondary Distribution of Fontaine stages during follow-up as compared to baseline. The percentage of patients with Fontaine stages I to IV will be determined. 6-months follow-up
Secondary Distribution of Fontaine stages during follow-up as compared to baseline. The percentage of patients with Fontaine stages I to IV will be determined. 12-months follow-up
Secondary Primary sustained clinical improvement at 12 months. Primary sustained clinical improvement is defined as sustained upward shift of at least one category on the Rutherford/Fontaine classification without the need for repeated TLR in surviving patients. 12-months follow-up
Secondary Secondary sustained clinical improvement at 12 months. Secondary sustained clinical improvement is defined as sustained upward shift of at least one category on the Rutherford/Fontaine classification including the need for repeated TLR in surviving patients. 12-months follow-up
Secondary Improvement in disease-related health status, functioning and quality of life at follow-up as compared to baseline. This is scored by the Walking Impairment Questionnaire and EQ-5D questionnaire. 1-month follow-up
Secondary Improvement in disease-related health status, functioning and quality of life at follow-up as compared to baseline. This is scored by the Walking Impairment Questionnaire and EQ-5D questionnaire. 6-months follow-up
Secondary Improvement in disease-related health status, functioning and quality of life at follow-up as compared to baseline. This is scored by the Walking Impairment Questionnaire and EQ-5D questionnaire. 12-months follow-up
Secondary Ankle Brachial Index (ABI) during follow-up as compared to baseline. 1-month follow-up
Secondary Ankle Brachial Index (ABI) during follow-up as compared to baseline. 6-months follow-up
Secondary Ankle Brachial Index (ABI) during follow-up as compared to baseline. 12-months follow-up
Secondary Occurrence of prolonged hospitalization compared to local standard of care (SOC). When the patient leaves the hospital after the procedure. Immediately after the procedure
Secondary Time taken off from work for the procedure Consists of:
Initial sick leave after the surgery
Additional sick leave
Leave taken by friends/relatives for patient care
1-month follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1